美国 · SEC FORM 4
Tango Therapeutics, Inc.
TNGX · Nasdaq · CIK 0001819133 · Healthcare · Biotechnology
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
27 同一窗口内观察到的 Form 4 交易行
14 sales · 13 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2024-11-18 · Rothenberg Mace · $37.8K
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出中等
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
Crystal AdamPresident, R&D
○▼○▼○▼○▼○▼○▼
Lee SungDirector
○○
Azelby RobertDirector
○
Rothenberg MaceDirector
○
Ketchum John BDirector
○
Calhoun Lesley AnnDirector
○
● 买入▼ 卖出○ 其他
Showing the six most active owners; 2 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2024-11-18 · Rothenberg Mace.
近期 Form 4 活动
0买入
26卖出
21其他 Form 4 交易行
25SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出14 sale line(s) · 仅供背景
其他13 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 44,500,110
- 上期报告
- 41,872,812
- 日均成交量
- 3,547,777
- 回补天数
- 12.5
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2024-11-18 | Rothenberg Mace | 买入 (P) | Common Stock | 10,000 | USD 3.78 | USD 37,800 | SEC 申报 ↗ |
| 2024-11-14 | Rothenberg Mace | 买入 (P) | Common Stock | 10,000 | USD 3.62 | USD 36,200 | SEC 申报 ↗ |
| 2023-10-16 | Boxer Asset Management Inc.; Boxer Capital, LLC; Davis Aaron I.; LEWIS JOSEPH; MVA Investors, LLC | 买入 (P) | Common Stock | 500,000 | USD 6.84 | USD 3,420,000 | SEC 申报 ↗ |
| 2023-10-16 | Boxer Asset Management Inc.; Boxer Capital, LLC; Davis Aaron I.; LEWIS JOSEPH; MVA Investors, LLC | 买入 (P) | Common Stock | 500,000 | USD 6.84 | USD 3,420,000 | SEC 申报 ↗ |
| 2023-10-13 | Boxer Asset Management Inc.; Boxer Capital, LLC; Davis Aaron I.; LEWIS JOSEPH; MVA Investors, LLC | 买入 (P) | Common Stock | 750,000 | USD 7.07 | USD 5,302,500 | SEC 申报 ↗ |
| 2023-10-13 | Boxer Asset Management Inc.; Boxer Capital, LLC; Davis Aaron I.; LEWIS JOSEPH; MVA Investors, LLC | 买入 (P) | Common Stock | 750,000 | USD 7.07 | USD 5,302,500 | SEC 申报 ↗ |
| 2023-08-11 | Boxer Asset Management Inc.; Boxer Capital, LLC; Davis Aaron I.; LEWIS JOSEPH; MVA Investors, LLC | 买入 (P) | Common Stock | 475,000 | USD 5.15 | USD 2,446,250 | SEC 申报 ↗ |
| 2022-10-13 | Boxer Asset Management Inc.; Boxer Capital, LLC; Davis Aaron I.; LEWIS JOSEPH; MVA Investors, LLC | 买入 (P) | Common Stock | 70,000 | USD 4.65 | USD 325,500 | SEC 申报 ↗ |
| 2022-10-12 | Boxer Asset Management Inc.; Boxer Capital, LLC; Davis Aaron I.; LEWIS JOSEPH; MVA Investors, LLC | 买入 (P) | Common Stock | 50,000 | USD 4.43 | USD 221,500 | SEC 申报 ↗ |
| 2022-10-11 | Boxer Asset Management Inc.; Boxer Capital, LLC; Davis Aaron I.; LEWIS JOSEPH; MVA Investors, LLC | 买入 (P) | Common Stock | 117,000 | USD 4.25 | USD 497,250 | SEC 申报 ↗ |
| 2022-10-06 | Boxer Asset Management Inc.; Boxer Capital, LLC; LEWIS JOSEPH | 买入 (P) | Common Stock | 70,394 | USD 4.06 | USD 285,800 | SEC 申报 ↗ |
| 2022-10-05 | Boxer Asset Management Inc.; Boxer Capital, LLC; LEWIS JOSEPH | 买入 (P) | Common Stock | 86,000 | USD 3.89 | USD 334,335 | SEC 申报 ↗ |
| 2022-10-04 | Boxer Asset Management Inc.; Boxer Capital, LLC; LEWIS JOSEPH | 买入 (P) | Common Stock | 25,606 | USD 3.67 | USD 93,974 | SEC 申报 ↗ |
| 2020-09-08 | BCTG Holdings, LLC | 买入 (P) | Common Stock | 533,500 | USD 10.00 | USD 5,335,000 | SEC 申报 ↗ |
Form 4 申报证据
47 transaction lines in the latest 365-day window; 152 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Crystal Adam | 卖出 (S) | Common Stock | 27,000 | USD 24.47 | USD 660,796 | SEC 申报 ↗ |
| 2026-10-01 | Crystal Adam | 期权行权／转换 (M) | Common Stock | 27,000 | USD 5.20 | USD 140,400 | SEC 申报 ↗ |
| 2026-09-22 | Newcomb Jessica | 卖出 (S) | Common Stock | 8,200 | USD 24.22 | USD 198,615 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Crystal Adam | 卖出 (S) | Common Stock | 27,000 | USD 24.47 | USD 660,796 | SEC 申报 ↗ |
| 2026-10-01 | Crystal Adam | 期权行权／转换 (M) | Common Stock | 27,000 | USD 5.20 | USD 140,400 | SEC 申报 ↗ |
| 2026-09-22 | Newcomb Jessica | 卖出 (S) | Common Stock | 8,200 | USD 24.22 | USD 198,615 | SEC 申报 ↗ |
| 2026-09-01 | Crystal Adam | 卖出 (S) | Common Stock | 27,000 | USD 22.37 | USD 603,990 | SEC 申报 ↗ |
| 2026-09-01 | Crystal Adam | 期权行权／转换 (M) | Common Stock | 27,000 | USD 5.20 | USD 140,400 | SEC 申报 ↗ |
| 2026-08-03 | Crystal Adam | 卖出 (S) | Common Stock | 27,000 | USD 27.24 | USD 735,500 | SEC 申报 ↗ |
| 2026-08-03 | Crystal Adam | 期权行权／转换 (M) | Common Stock | 27,000 | USD 5.20 | USD 140,400 | SEC 申报 ↗ |
| 2026-07-01 | Crystal Adam | 卖出 (S) | Common Stock | 27,000 | USD 29.59 | USD 798,888 | SEC 申报 ↗ |
| 2026-07-01 | Crystal Adam | 期权行权／转换 (M) | Common Stock | 27,000 | USD 5.20 | USD 140,400 | SEC 申报 ↗ |
| 2026-06-19 | Azelby Robert | 奖励／授予 (A) | Common Stock | 5,740 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-05 | Rothenberg Mace | 奖励／授予 (A) | Common Stock | 4,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-05 | Lee Sung | 奖励／授予 (A) | Common Stock | 570 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-05 | Ketchum John B | 奖励／授予 (A) | Common Stock | 4,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-05 | Calhoun Lesley Ann | 奖励／授予 (A) | Common Stock | 4,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-01 | Crystal Adam | 卖出 (S) | Common Stock | 27,000 | USD 22.88 | USD 617,647 | SEC 申报 ↗ |
| 2026-06-01 | Crystal Adam | 期权行权／转换 (M) | Common Stock | 27,000 | USD 5.20 | USD 140,400 | SEC 申报 ↗ |
| 2026-05-01 | Gall Matthew | 奖励／授予 (A) | Common Stock | 40,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-01 | Crystal Adam | 卖出 (S) | Common Stock | 27,000 | USD 21.22 | USD 573,021 | SEC 申报 ↗ |
| 2026-05-01 | Crystal Adam | 期权行权／转换 (M) | Common Stock | 27,000 | USD 5.20 | USD 140,400 | SEC 申报 ↗ |
| 2026-04-29 | Lee Sung | 奖励／授予 (A) | Common Stock | 12,300 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-15 | Crystal Adam | 卖出 (S) | Common Stock | 38,460 | USD 25.00 | USD 961,500 | SEC 申报 ↗ |
| 2026-04-15 | Crystal Adam | 期权行权／转换 (M) | Common Stock | 38,460 | USD 5.20 | USD 199,992 | SEC 申报 ↗ |
| 2026-04-01 | Crystal Adam | 卖出 (S) | Common Stock | 27,000 | USD 21.20 | USD 572,400 | SEC 申报 ↗ |
| 2026-04-01 | Crystal Adam | 期权行权／转换 (M) | Common Stock | 27,000 | USD 5.20 | USD 140,400 | SEC 申报 ↗ |
| 2026-03-25 | Crystal Adam | 卖出 (S) | Common Stock | 12,000 | USD 20.11 | USD 241,320 | SEC 申报 ↗ |
| 2026-03-25 | Crystal Adam | 期权行权／转换 (M) | Common Stock | 12,000 | USD 5.20 | USD 62,400 | SEC 申报 ↗ |
| 2026-03-05 | Crystal Adam | 卖出 (S) | Common Stock | 20,251 | USD 15.00 | USD 303,765 | SEC 申报 ↗ |
| 2026-02-25 | Crystal Adam | 卖出 (S) | Common Stock | 54,345 | USD 12.77 | USD 693,986 | SEC 申报 ↗ |
| 2026-02-03 | Weber Barbara | 卖出 (S) | Common Stock | 30,519 | USD 12.27 | USD 374,376 | SEC 申报 ↗ |
| 2026-02-03 | Crystal Adam | 卖出 (S) | Common Stock | 18,452 | USD 12.27 | USD 226,350 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | TNGX |
| CIK | 0001819133 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 152 transaction lines from 2020-09-08 to 2026-10-01 15 P purchase lines · 85 S sale lines · 52 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.